Rosen Law Firm is investigating potential securities claims against The Ensign Group following allegations that the company misled investors by understaffing nursing homes and manipulating quality metrics. This came after a short seller report accused Ensign of prioritizing profits over patient care, causing the stock to drop 8.15% on June 8, 2026. Investors who bought Ensign securities may join a class action lawsuit seeking compensation without upfront costs. The Rosen Law Firm, known for its expertise in securities class actions, is preparing to represent affected shareholders.
The Ensign Group, Inc. is the subject of a securities class action investigation. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 16, 2026 02:01 WIB: out of 91 priced US health-sector stocks, 24 rose and 66 fell. Notable movers include Summit Therapeutics Inc (SMMT) down 5.37%, BridgeBio Pharma Inc (BBIO) down 5.35%, and Neurocrine Biosciences Inc (NBIX) down 4.93%.
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
